ImmuCell Co. (NASDAQ:ICCC) Short Interest Down 22.8% in March

ImmuCell Co. (NASDAQ:ICCC) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 13,200 shares, a drop of 22.8% from the February 28th total of 17,100 shares. Based on an average trading volume of 8,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.2% of the shares of the stock are short sold.

Institutional Investors Weigh In On ImmuCell

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dauntless Investment Group LLC bought a new position in shares of ImmuCell during the 4th quarter valued at about $676,000. Geode Capital Management LLC lifted its stake in ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 7,878 shares during the last quarter. Northern Trust Corp boosted its holdings in ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after buying an additional 14,982 shares in the last quarter. Citadel Advisors LLC bought a new stake in ImmuCell during the fourth quarter worth approximately $149,000. Finally, Mesirow Financial Investment Management Inc. grew its position in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after buying an additional 12,178 shares during the last quarter. 13.47% of the stock is currently owned by institutional investors.

ImmuCell Price Performance

NASDAQ:ICCC traded up $0.21 during midday trading on Tuesday, hitting $5.00. 77,283 shares of the stock were exchanged, compared to its average volume of 19,304. The company has a market capitalization of $44.56 million, a price-to-earnings ratio of -10.00 and a beta of 0.62. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. ImmuCell has a one year low of $3.34 and a one year high of $5.82. The business has a 50-day moving average price of $5.11 and a two-hundred day moving average price of $4.47.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Tuesday, February 25th. The biotechnology company reported $0.06 EPS for the quarter. The company had revenue of $7.75 million for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.